Physical Performance, Toxicity, and Quality of Life as Assessed by the Physician and the Patient

Authors

  • Minna-Liisa Luoma From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Liisa Hakamies-Blomqvist From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Johanna Sjöström From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Hennig Mouridsen From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Anna Pluzanska From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Per Malmström From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Nils Olof Bengtsson From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Ragnar Hultborn From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Björn Ostenstaad From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Ingvil Mjaaland From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Vahur Valvere From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Erik Wist From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Gudjon Baldursson From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Johan Ahlgren From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)
  • Carl Blomqvist From the Department of Psychology, University of Helsinki, Finland (M.-L. Luoma), University of Helsinki Swedish School of Social Science, Finland (L. Hakamies-Blomqvist), Helsinki University Central Hospital, Finland (J. Sjo stro m), University Hospital Rigshospitalet, Copenhagen, Denmark (H. Mouridsen),Department of Oncology, Medical University, Lodz, Poland (A. Pluzanska), University Hospital, Lund, Sweden (P. Malmstrom), University Hospital, Umea , Sweden (N.O. Bengtsson), Sahlgrenska Sjukhuset, Go teborg, Sweden (R. Hultborn), Ulleva l Hospital, Oslo, Norway (B. Ostenstaad), Rogaland Central Hospital, Stavanger, Norway (Ingvil Mjaaland), Estonian Cancer Center, Tallinn, Estonia (V. Valvere), Department of Oncology, Troms Regional Hospital, Norway (E. Wist), Department of Oncology, University Hospital of Iceland, Reykjavik, Iceland (G. Baldursson), Department of Oncology, Medical Centre Hospital, rebro, Sweden (J. Ahlgren), Department of Oncology, Uppsala University Hospital, Sweden (C. Blomqvist)

DOI:

https://doi.org/10.1080/028418602317314055

Abstract

The aim of this study was to study the relationship between physician-assessed quality of life parameters, i.e., toxicity and physical performance, and patients' self-reports of their quality of life (QoL). QoL was assessed at baseline and before each treatment, using the EORTC QLQ-C30. The WHO performance score (PS) and toxicity were assessed in physician interviews. The correlations between the WHO PS and the QLQ-C30 functioning scale scores varied from weak to moderate, depending on the scale. Strongest associations were found in physical-, social-, and role functioning, and in the global QoL. The QLQ-C30 nausea/vomiting and diarrhea scales correlated moderately to corresponding WHO scores. A multiple linear regression analysis was used to analyze the contribution of WHO PS and toxicity variables to the global QoL. The best model explained only 16% of the variance of the global QoL score. The present findings highlight the importance of independent QoL assessments focused on those aspects of QoL not captured in clinical interviews with the physician.

Downloads

Download data is not yet available.

Downloads

Published

2002-01-01

How to Cite

Luoma, M.-L., Hakamies-Blomqvist, L., Sjöström, J., Mouridsen, H., Pluzanska, A., Malmström, P., … Blomqvist, C. (2002). Physical Performance, Toxicity, and Quality of Life as Assessed by the Physician and the Patient. Acta Oncologica, 41(1), 44–49. https://doi.org/10.1080/028418602317314055

Issue

Vol. 41 No. 1 (2002): Acta Oncologica

Section

Articles